While the last decades have seen great progress in the treatment of many cancer types due to advancements in conventional therapies as well as the recent introduction of personalized therapeutic approaches, metastasis and resistance to pharmacological interventions impact clinical prognosis of a large number of patients. Here, suppression and evasion of the immune system represent a common strategy of advanced malignant neoplasias and the reactivation of the immune system can provide a supportive or alternative strategy especially for patients with a high tumor burden and advanced disease.
Recent approaches have utilized a number of strategies to activate specific tumor directed immune responses or alternatively to block elements of cancer specific immune escape mechanisms. Advances in molecular profiling technologies - including the analysis of individual cells' genomes and transcriptomes - have opened incredible opportunities in investigating the molecular foundations of immune escape mechanisms as well as to understand specific mechanisms of the immune system with possible application to cancer therapeutics.
In this research topic we aim to gather articles describing recent advances in cancer associated immunobiology, including discoveries on new mechanisms and targets, as well as summarizing the state of immunotherapy advances in clinical settings. Emphasis will be on studies utilizing "-omics" methodologies and large-scale data analysis, preferably in a combination of experimental and computational approaches.
This Research Topic is primarily for research on, but not solely limited to, the following:
1. Identification of new tumor-host interactions and targeting them via small molecule and immunotherapeutic approaches.
2. (CAR) T-cell immunotherapy and other immunotherapy strategies.
3. Oncolytic virus immunotherapy.
4. Development of new experimental models that assess the specific responses of cancer cells and immune system to therapeutics.
5. The role of tumor microenvironment in therapy response
6. Identify and therapeutically target alterations in tumor and survival signaling pathways.
7. Characterization of tumors at the molecular, genomic, and cellular level and utilize this information to guide therapeutic strategies for improving clinical outcomes.
8. Epigenetic regulation of tumor microenvironment and immunotherapy
While the last decades have seen great progress in the treatment of many cancer types due to advancements in conventional therapies as well as the recent introduction of personalized therapeutic approaches, metastasis and resistance to pharmacological interventions impact clinical prognosis of a large number of patients. Here, suppression and evasion of the immune system represent a common strategy of advanced malignant neoplasias and the reactivation of the immune system can provide a supportive or alternative strategy especially for patients with a high tumor burden and advanced disease.
Recent approaches have utilized a number of strategies to activate specific tumor directed immune responses or alternatively to block elements of cancer specific immune escape mechanisms. Advances in molecular profiling technologies - including the analysis of individual cells' genomes and transcriptomes - have opened incredible opportunities in investigating the molecular foundations of immune escape mechanisms as well as to understand specific mechanisms of the immune system with possible application to cancer therapeutics.
In this research topic we aim to gather articles describing recent advances in cancer associated immunobiology, including discoveries on new mechanisms and targets, as well as summarizing the state of immunotherapy advances in clinical settings. Emphasis will be on studies utilizing "-omics" methodologies and large-scale data analysis, preferably in a combination of experimental and computational approaches.
This Research Topic is primarily for research on, but not solely limited to, the following:
1. Identification of new tumor-host interactions and targeting them via small molecule and immunotherapeutic approaches.
2. (CAR) T-cell immunotherapy and other immunotherapy strategies.
3. Oncolytic virus immunotherapy.
4. Development of new experimental models that assess the specific responses of cancer cells and immune system to therapeutics.
5. The role of tumor microenvironment in therapy response
6. Identify and therapeutically target alterations in tumor and survival signaling pathways.
7. Characterization of tumors at the molecular, genomic, and cellular level and utilize this information to guide therapeutic strategies for improving clinical outcomes.
8. Epigenetic regulation of tumor microenvironment and immunotherapy
